Bayer wins PMA for Betaconnect electronic autoinjector

Bayer (ETR:BAYN) said Monday it won FDA premarket approval for its Betaconnect electronic autoinjector for treating relapsing-remitting multiple sclerosis patients on the drug Betaseron. The Betaconnect is the 1st and only electronic autoinjector if its kind to treat RRMS, Whippany, N.J.-based Bayer said. “Bayer has a long legacy of supporting and providing services for the RRMS community. Betasaron was the 1st disease-modifying therapy approved by the FDA to treat RRMS patients, and today we are pleased to offer the 1st and only electronic auto injector for those living with the disease,” Bayer neurology veep Klaus Marten said in prepared remarks. The Betaconnect device allows for customizable injection speed and depth settings, and comes with an optional back-up reminder to inform patients when its time for their next injection. The device also comes with visual and audio end-of-dose indications, as the needle injection and retraction are automatic, the company said. “Offering new options to individuals with MS to help manage their disease is important since ‘1 size does not fit all’ when considering MS treatment,” Multiple Sclerosis Association of America CEO Douglas Franklin said in a press release. The Betaconnect device will be available for Betasaron patients beginning in early 2016, Bayer said. The post Bayer wins PMA for Betaconnect electronic autoinjector appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug Pumps Food & Drug Administration (FDA) Neurological Bayer HealthCare Source Type: news

Related Links:

AbstractPurpose of ReviewNeurotrophic keratopathy (NK) is a challenging ophthalmological disease. In this review, we present an updated evidence-based summary on the pathophysiology, classification, diagnosis, and how novel therapies have changed the management of NK.Recent FindingsNew specific medical and surgical modalities are emerging, such as Cenegermin (Oxervate ®, Dompé) and neurotization procedures, which are changing the paradigm of the treatment of NK. In addition, more diagnostic resources are available, such as corneal confocal microscopy in vivo, non-contact esthesiometers, and common ocular surface...
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research
ConclusionsRelapse rates with treatment with FTY, DMF and TERI were similar. Patients treated with DMF showed less sustained disability progression for 12  weeks than FTY-treated patients. However, FTY and DMF treatment was associated with more likely EDSS regression for 12 and 24 weeks and a lower probability for treatment interruption as compared to TERI-treated patients.
Source: Journal of Neurology - Category: Neurology Source Type: research
AbstractPurposeManual measures such as corpus callosum index, normalized corpus callosum area, and width of the third ventricle are potential biomarkers for brain atrophy. In this work, we investigate their suitability to assess the neurodegenerative component of multiple sclerosis (MS) by comparing them to volumetric measures and expanded disability status scale (EDSS).MethodsFifty-eight patients with a clinically isolated syndrome, 48 MS patients treated with interferon β, and 26 treated with natalizumab underwent a brain MRI at baseline and after 1 year. Manual measures were evaluated by two observers usi...
Source: Neuroradiology - Category: Radiology Source Type: research
Nature Reviews Neurology, Published online: 03 April 2020; doi:10.1038/s41582-020-0356-0Trigeminal neuralgia linked to demyelination in multiple sclerosis
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research
In this study, we tested the presence of MOG-Ab and AQP4-Ab in 57 children at first onset of acute neurological symptoms; three clinical subgroups were identified: 12 patients had acquired inflammatory demyelinating CNS syndromes, 11 had other auto immune/immune-mediated disorders of the central and peripheral nervous system and 34 had non-immune-mediated CNS disorders. MOG-Abs were found positive only in a subset of cases in the subgroup with acquired inflammatory demyelinating CNS syndromes (in 2/12 patients, both with non-MS phenotype) and in none of the patients with other autoimmune and immune-mediated disorders of th...
Source: Neurological Sciences - Category: Neurology Source Type: research
In conclusion, oculomotor impairment is a common component of disability in MS patients and should be considered when managing this type of patients. More research is still needed to know the real impact of this disease on binocular vision and accommodation. PMID: 32228341 [PubMed - as supplied by publisher]
Source: Seminars in Ophthalmology - Category: Opthalmology Tags: Semin Ophthalmol Source Type: research
Fatigue and poor sleep quality are among the most common patient-reported problems associated with multiple sclerosis (MS). Social support, on the other hand, is often found to be positively associated with quality of life in patients with neurological dis...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Publication date: Available online 1 April 2020Source: Journal of Clinical NeuroscienceAuthor(s): Emily Cheung, Jessica Hafner, Yi-Ching Lee, Sharon Coward, Amy Lofts, John Parratt, Karl Ng
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 31 March 2020Source: Neurología (English Edition)Author(s): L.A. Rodríguez de Antonio, I. García Castañón, M.J. Aguilar-Amat Prior, I. Puertas, I. González Suárez, C. Oreja Guevara
Source: Neurologia - Category: Neurology Source Type: research
Publication date: Available online 31 March 2020Source: The Brazilian Journal of Infectious DiseasesAuthor(s): Razieh Amini, Sajad karampoor, Hamid Zahednasab, Hossein Keyvani, Masoud Gheiasian, Farid Azizi Jalilian
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
More News: Betaseron | Brain | Medical Devices | Multiple Sclerosis | Neurology